NMPA Holds Launch Meeting for Regulatory Science Innovation Research Base and Medical Device Innovation Seminar in Beijing

NMPA Holds Launch Meeting for Regulatory Science Innovation Research Base and Medical Device Innovation Seminar in Beijing

On July 4, 2026, the National Medical Products Administration (NMPA) held the launch meeting of the Regulatory Science Innovation Research Base (Medical Devices and Cosmetics) and the Medical Device Innovation Seminar in Beijing. Lei Ping, Member of the Party Leadership Group and Deputy Administrator of NMPA, attended the meeting and delivered a speech.

The meeting heard reports on the base construction plan and the progress of four innovation cooperation platforms: high-end medical equipment, artificial intelligence-enabled medical devices, biomaterials, and in vitro diagnostic medical devices. Experts from the academic committee of the base provided opinions and suggestions on the future layout of regulatory science for medical devices and cosmetics.

The meeting noted that the integrated development of 'one base and four platforms' is a regulatory science innovation model that NMPA is focused on building. Host institutions should aim at international frontiers, ensure the base and platforms get off to a good start, accelerate the output of innovative results serving the high-quality development of the pharmaceutical and medical device industry, and effectively safeguard the public's needs for medical devices and cosmetics.

Relevant departments and divisions of NMPA, the Beijing Municipal Medical Products Administration, the National Institutes for Food and Drug Control (NIFDC), and the Center for Medical Device Evaluation (CMDE) attended the meeting.

The meeting marks a new stage in which China's medical device regulatory science is moving toward systematic integration.

Source and Applicability

Source institution: NMPA Medical Devices. Original date: July 6, 2026. Publication time on this site: July 9, 2026, 15:00. Source: NMPA Medical Devices.

This article is compiled and organized from public information published by NMPA Medical Devices. Source: https://www.nmpa.gov.cn/yaowen/ypjgyw/ylqxyw/20260706145121172.html. Specific requirements are subject to the latest official release of the regulatory authority.

AIMEILI Regulatory Interpretation and Business Impact

Why This Matters for Medical Device Companies

For global medical device manufacturers, distributors, contract research organizations and regulatory affairs teams, the launch of the base and the advancement of the four platforms signal that NMPA is moving toward a more integrated regulatory science system. Companies should monitor how future regulatory science outputs may affect product registration pathways, classification determinations, clinical evaluation and quality system requirements in China.

Registration Pathways and Classification

Because the base and platforms focus on high-end medical equipment, artificial intelligence-enabled medical devices, biomaterials and in vitro diagnostics, NMPA may issue specific classification guidance or registration review guidelines for these areas. Companies should assess whether existing products may need reclassification due to technology iteration or whether additional clinical evaluation data may be required. For artificial intelligence-enabled medical devices, software validation and algorithm verification requirements may be further refined, which can affect registration strategy.

Technical Documentation and Clinical Evaluation

Regulatory science innovation often introduces more scientific evaluation methods and standards. In biomaterials, in vitro alternative test methods may be more widely accepted, reducing reliance on animal testing. For high-end medical equipment, clinical evaluation pathways may require support from real-world clinical data rather than reliance solely on equivalence comparison. Companies should evaluate the completeness of their technical documentation in advance, especially clinical evidence for new materials or complex algorithms.

Quality Systems and Post-Market Obligations

The outputs of the 'one base and four platforms' model may translate into new quality management system requirements, such as change management for continuous learning and version updates of artificial intelligence-enabled medical devices. Regulatory science innovation may also promote more efficient post-market surveillance mechanisms. Companies should ensure that complaint handling and adverse event reporting systems can respond promptly to new requirements.

IVD and Companion Diagnostics

For IVD companies, the in vitro diagnostic medical device platform is expected to focus on areas such as precision diagnostics and companion diagnostics. Guidance may be issued for synchronized development of companion diagnostic reagents and drugs. Companies should adjust their R and D and registration collaboration strategies and strengthen communication with pharmaceutical companies.

Practical Compliance Actions

• Record the official source link, publication date, applicable product scope and potentially affected areas in the regulatory tracking log.
• Have regulatory, quality, R and D, and sales teams jointly determine whether labels, instructions for use, clinical evaluation, risk management or test reports need updating.
• If products are already marketed locally or registration applications have been submitted, assess whether the local authorized representative, importer, distributor and after-sales team need to take communication, change, supplementary explanation or post-market surveillance measures.

Documentation to Review

Companies should prioritize reviewing intended use, classification basis, ISO 13485 quality system certification, risk management file, performance verification data, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents and existing registration certificates.

Common Risks

• Unclear classification determination.
• Incomplete evidence chains in documentation.
• Labels and instructions for use not localized.
• Unclear responsibilities of authorized representatives.
• Insufficient post-market maintenance arrangements.

AIMEILI View

The launch meeting and the advancement of the four platforms reflect NMPA's forward-looking layout in medical device regulatory science. For Chinese medical device manufacturers, this is not only a policy signal but may also directly affect future registration submissions and technical compliance requirements.

In summary, companies should closely track any research outputs, guidelines or standards issued by the base and platforms and adjust internal compliance strategies in a timely manner. For high-end devices, artificial intelligence-enabled products, biomaterials and IVD products that are under registration or planned for registration, companies should proactively communicate with regulators and participate in relevant seminars to seize the initiative and avoid compliance risks.

From an international registration practice perspective, this NMPA update should not be read as ordinary news only. Companies should first determine whether it concerns regulation and policy, guidelines and standards, product approval, recall and safety, quality systems or post-market regulatory information, because each type triggers different internal actions. If a company is advancing registration projects in relevant markets, it should add the update to the target market regulatory tracking table and confirm whether it affects product classification, registration pathway, applicant, local agent responsibilities or certificate maintenance.

For Chinese medical device manufacturers, the direct impact of this update is likely to appear in documentation consistency and evidence chain management. Companies should check existing technical files, risk management reports, performance verification data, clinical evaluation or clinical evidence, labels and instructions for use, quality system certificates and post-market surveillance documents to confirm whether they still support the latest regulatory expectations in target markets. If the information involves safety notices, recalls, product approvals or regulatory meetings, companies should also assess whether similar products, similar technology routes or similar risk points may receive focused attention from reviewers.

The value of this news is not simply knowing what the regulator has published, but converting public information into executable compliance actions. For companies preparing multi-country registrations, particular attention should be paid to the boundaries of document reuse across markets: the same CE, FDA, NMPA, ISO 13485 or MDSAP documentation may serve as core evidence in one country but may require localized explanations, language labels, authorized representative documents or post-market maintenance plans in another. AIMEILI recommends a brief documentation gap review after each important regulatory update to avoid reactive deficiency responses, changes or renewals.

FAQ

Can this article be used directly as a basis for regulatory submission?

No. This article is for preliminary understanding and project assessment. Formal submissions must be based on the latest requirements of the target country regulatory authority, the product classification conclusion and the company's actual documentation status.

What should companies do first after seeing this update?

We recommend conducting a documentation gap assessment first and confirming whether the update affects the registration pathway, technical documentation, labels, quality system or post-market maintenance.

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team. Source principle: priority is given to official regulatory authorities, international organizations, standards organizations and public regulatory materials; industry media and project experience are used only as auxiliary judgment.

Applicability boundaries: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country regulatory authority, testing conclusions or legal opinions.

Need to Assess Your Registration Pathway?

Please provide the product name, intended use, target countries and existing documentation base. AIMEILI can assist in assessing the registration pathway, documentation gaps and compliance risks.

Contact AIMEILI for further support.